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Introduction
Over the past decade, continuous bioprocessing has been viewed as a game changer in biopharmaceutical manufacturing,
poised to unlock significant improvements in production cost. Today, solutions exist to enable continuous bioprocessing
for nearly every step in the biomanufacturing process flow. However, implementation of fully integrated continuous
platforms is limited.

aspects, flexibility, simplicity, and sustainability are often considered equally important in the decision-making process.
Continuous bioprocessing cannot be the goal for all scenarios. Instead, it should be viewed as one tool in the toolbox of
solutions for modern, intensified processing. Suitability and output should be evaluated for the individual process needs
and objectives.

The slower adoption curve suggests one of two things: either continuous bioprocessing is not a game changer for production
costs, or the decision to implement innovative manufacturing solutions involves much more than financials. Indeed, regulatory

Within this context, we have reviewed the impact of various combinations of tools for intensified bioprocessing of monoclonal
antibodies (mAb). Further, we have created a process concept for simplified connected and semi-continuous processing.

Upstream intensification options
There is a multitude of options available to intensify upstream operations over traditional fed-batch setups. Perfusion applied
in different ways may improve productivity, but it is important to ensure benefits outweigh the higher media costs associated.
Downstream strategies will also be impacted by upstream processes, and a holistic view should guide your choice of process

technology. To assist in this, we have created the Process Intensifier application an interactive calculator for comparison of
intensification impact over both upstream and capture operations in mAb processing. The Process Intensifier application is
available cytiva.com/processintensifier.
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Fig 1. Upstream intensification options. Upper bar represents typical performance for fed-batch process, lower bar relative performance for respective intensification technology.

Downstream intensification options
Essential considerations
• Process intensification should not compromise process robustness
or scalability, nor increase process risk as:
– Supply shortages of life-saving drugs may be detrimental
to patients
– Lost sales will rapidly offset production cost savings for
high-margin products
– Quality defects trigger resource-consuming avalanches
of investigations, CAPAs, and operator trainings
– Robust cleaning methods are vital to avoid costly bioburden
incidents
• Buffer management strategy is key to success, in-line conditioning
or dilution skids may significantly reduce facility footprint

Intermittent perfusion
Protein A capture
• Use caution with the volumetric productivity measure. It is not
a measure of:
– Footprint as it does not consider equipment size
– Process economics as it does not consider re-usability,
adsorber cost, buffer consumption, etc.
• Cost profiles differ between production scenarios, for example:
– In clinical manufacturing using fed-batch production
bioreactors, quick resin lifetime utilization will reduce costs
– At high capacity and lifetime utilization, resin costs may be
as low as $2 to 3/g drug substance for MabSelect PrismA™
– Flow kits, columns, buffers, and other consumable costs
may offset resin savings and should also be considered
– Different strategies in clinical and commercial production
add to development and characterization time and costs

• Novel concept for simplified semi-continuous processing
• Combines the small footprint from continuous processes with the simplicity and
flexibility of batch processing
• Extensive cycling improves footprint and resin lifetime utilization
• Allows single column setup through pausing product output during non-loading
capture chromatography steps
• Downstream processing (DSP) train is connected and operates in batch mode
• Synchronized elution and loading allows elimination of surge tanks and separation
of product sub-lots throughout the DSP
• May eliminate need for residence time-distribution modeling
• Suitable for closed processing
• Runs on standard equipment
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Fig 2. Performance characteristics for different variants of Protein A capture chromatography (PCC = periodic counter-current chromatography).
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Fig 4. Intermittent perfusion, process timing example.
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Fig 3. Decision tree for choosing mAb capture strategy.

Essential considerations
• Post capture processing
• Flow-through purification or reduction of number of purification steps are powerful ways to intensify a process
• For platform processes, ensure sufficient impurity reduction across the full range of molecule variants in scope
• Continuous processing has compelling benefits in suitability for closed processing, automation and real time release
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Conclusions
Different processes call for different intensification strategies. In choosing a strategy, it is
important to be clear on what parameters are the most critical to improve and what tradeoffs
the strategy may require.
Before deciding on a process setup, you should apply a holistic view across the full process.
In addition to CapEx and OpEx implications, parameters such as process simplicity, flexibility,
and portability should be considered.
To combine footprint and automation benefits of continuous processing with the simplicity
and flexibility of batch processing, we have created the Intermittent Perfusion process concept.

